Terumo Cardiovascular Group, a provider of cardiovascular surgery technologies, announced the launch of its smallest full-size adult oxygenator, the Capiox NX19 Oxygenator with UltraPrime Technology.
17 Jan 2019
02 Jan 2019
AIT nears deal to license commercial rights of ventilator compatible NOgenerator and delivery system
AIT Therapeutics announced that, having previously signed a letter of intent (LOI), a definitive agreement to license the commercial rights for its novel cylinder free ventilator compatible nitric oxide (NO) generator and phasic-flow delivery system (GeNOvent) for use in the hospital setting at NO concentrations < 80 ppm to a commercial partner is close to being finalized.
11 Dec 2018
ALung Technologies, a provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, has announced significant progress in its hemolung clinical trial programs.
04 Dec 2018
Connected health company ResMed has agreed to acquire US-based digital therapeutics firm, Propeller Health, in a deal worth $225m.
28 Nov 2018
Vectura Group’s drug-device, VR475, has failed to meet its primary endpoint in adult and adolescent patients with severe uncontrolled asthma in the phase III study.
27 Nov 2018
Medical devices producer and OEM solutions partner Millar has secured expanded CE mark for its Mikro-Cath pressure catheter.
15 Nov 2018
Actuated Medical, a developer of medical devices that integrate electronically controlled motion technologies, has received an innovative technology contract from Vizient for its TubeClear System.
09 Nov 2018
Hikma Pharmaceuticals has signed an agreement with Vectura Group for the worldwide development and commercialization of the generic versions of GSK's Ellipta portfolio.
23 Oct 2018
Regenerative medicine company CollPlant and biotechnology firm United Therapeutics have signed a license, development and commercialization agreement for 3D bioprinting of solid-organ scaffolds for human transplants.
09 Oct 2018
Interventional spray cryotherapy technology platforms developer CSA Medical has secured $23m in venture debt and equity financing to advance its two cryospray therapy platforms, truFreeze and Rejuvenair.